The QualityStocks Daily Wednesday, April 6th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(TUFN) $12.9200 +43.08%

QualityStocks(SFUN) $4.3927 +17.14%

NetworkNewsWire(CNSP) $0.4239 +11.64%

The QualityStocks Daily Stock List

Mobiquity Technologies, Inc. (MOBQ)

MarketBeat, QualityStocks, TradersPro, PennyStocks24, StockMister, Penny Stock Circle, 1-2-3 Stock Alerts, The Cervelle Group, StockRockandRoll, Stock Commander, SmallCapVoice, ResearchOTC, PennyStockLocks.com and PennyPickAlerts reported earlier on Mobiquity Technologies, Inc. (MOBQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mobiquity Technologies, Inc. operates a national location-based mobile advertising network. This network has developed a consumer-focused proximity network. Mobiquity Networks is a wholly-owned subsidiary of Mobiquity Technologies. Mobiquity Networks is the largest network of retail mall-based mobile advertising beacons in America. Mobiquity Networks is a next generation mobile location data intelligence and marketing company. Mobiquity Technologies is based in Garden City, New York.

Mobiquity Networks provides precise, unique, at-scale location based data and insights on consumers' real world behavior and trends. This is for use in marketing and research.

Mobiquity Technologies has exclusive agreements in hundreds of premier U.S. shopping malls. Its integrated group of unique location-based mobile advertising technologies enables retail and entertainment brands to execute personalized and contextually relevant experiences. This boosts brand awareness and incremental revenue.

Mobiquity Technologies is continuing to work to expand its location-based mobile advertising solutions to create "smart malls" in retail destinations throughout the U.S. employing Bluetooth-enabled iBeacon technology. By way of its subsidiaries, the Company provides brand marketing, advanced integrated marketing platforms, mobile marketing, social networks, Website development, and digital media solutions. It provides brand analysis and development, Website analysis and development, database analysis and building, and integrated marketing campaigns using direct mail, email marketing, mobile marketing, promotional products, and other mediums.

Furthermore, Mobiquity Technologies provides a proprietary Web development platform and delivers a content management system that puts content control back into the clients’ hands. The Company also provides hyper-local mobile marketing solutions. This includes a location-based marketing tool, which delivers digital content to Bluetooth or Wi-Fi enabled devices.

Mobiquity Technologies, Inc. (MOBQ), closed Wednesday's trading session at $2.1, up 29.6296%, on 76,522,956 volume. The average volume for the last 3 months is 76.523M and the stock's 52-week low/high is $1.20/$10.25.

Sunshine Biopharma (SBFM)

QualityStocks, Investor Ideas, PennyStocks24, Ceocast News, Stock Twiter, Gorilla Stock Trades, OTCPicks, MarketClub Analysis, Pennybuster, Jet-Life Penny Stocks, Fast Money Alerts, FeedBlitz, AllPennyStocks, Investor Stock Alerts, Ironman Stock, Greenbackers, 007 Stock Chat, Mina Mar Marketing Group, Winston Small Cap, Otcstockexchange, Penny Stock General, PennyStockSpy, Shiznit Stocks, Stock Roach, Stock Shock and Awe, StockHideout, Whisper from Wall Street and MassiveStockProfits reported earlier on Sunshine Biopharma (SBFM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma Inc. (OTC: SBFMD) is a pharmaceutical firm that is engaged in researching, developing and commercializing therapies for different forms of cancer.

The firm has its headquarters in Pointe-Claire, Canada and was incorporated in 2006, on August 31st. It is part of the drug wholesaler’s industry and operates in the healthcare sector under the biotech and pharma sub-industry.

The company is party to a license agreement with the University of Georgia to further advance developing a pair of anti-Covid-19 compounds in parallel with SBFM-PL4, its anti-Covid-19 lead compound. Its goal is to become a fully integrated pharmaceutical firm that offers proprietary and generic drugs for treating cancer and other chronic and acute indications. Its products include Essential 9, SBI-Finasteride, SBI-Bicalutamide, SBI-Letrozole, SBI-Anastrozol and Adva-27a.

Its product pipeline includes an anti-coronavirus treatment compound dubbed SBFM-PL4; a dietary supplement tablet named Essential 9 and a GEM-difluorinated C-glycoside derivative of podophyllotixin dubbed Adva-27a which is indicated for the treatment of liver, ovarian, colon, bladder, prostate, brain, lung, testicular, lymphoma, leukemia and other cancer types, as well as eliminating multidrug resistant cancer cells, including uterine sarcoma cells, small-cell lung cancer, breast cancer and pancreatic cancer. In addition to this, it also offers generic prescription drugs for treating benign prostatic hyperplasia, prostate cancer and breast cancer.

The American Cancer Society approximates that over a million individuals are diagnosed each year with cancer in the U.S., noting that more than 11 million Americans are currently living with cancer. The company may soon introduce a new cancer treatment into the market, which will be beneficial to patients suffering from these ailments as well as company stakeholders.

Sunshine Biopharma (SBFM), closed Wednesday's trading session at $6.29, up 12.1212%, on 73,819,410 volume. The average volume for the last 3 months is 73.085M and the stock's 52-week low/high is $0.0401/$10.50.

Allovir Inc. (ALVR)

Greenbackers, QualityStocks, SmarTrend Newsletters, PennyTrader Publisher, FeedBlitz, StockEgg, PennyStocks24, SmallCapInvestor.com, MicrocapVoice, MarketBeat, MadPennyStocks, OTCPicks, HotOTC, CRWEWallStreet, CoolPennyStocks, BUYINS.NET, BullRally, Investor Update, Penny Invest, Bull Warrior Stocks, PennyStockVille, Zacks, Stock Fortune Teller, Stock Stars, StockRich, StreetInsider, The Momentum Traders Network, The Online Investor, The Street, Wall Street News Alert and PennyInvest reported earlier on Allovir Inc. (ALVR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Allovir Inc. (NASDAQ: ALVR) is a clinical-stage cell therapy firm that is focused on conducting research on and developing allogeneic off-the-shelf multi-virus specific T cell therapies to treat and prevent viral-associated illnesses.

The firm has its headquarters in Waltham, Massachusetts and was incorporated in August 2013 by Ann M. Leen, John Wilson, Cliona M. Rooney, Hellen E. Heslop, Juan F. Vera and Malcolm K. Brenner. Prior to its name change in May 2019, the firm was known as ViraCyte Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company uses its proprietary and innovative technology platforms to target devastating viruses in patients suffering from T cell deficiencies who have a heightened risk of the life-threatening consequences of viral illnesses.

The enterprise’s product pipeline comprises of its pre-clinical and clinical development product candidates, which include its ALVR107 formulation, which has been developed for the treatment of hepatitis B; its ALVR109 drug for the treatment of the coronavirus and SARS-CoV-2; its ALVR108 formulation; and its ALVR106 candidate for the treatment of human metapneumonia, parainfluenza virus, influenza and respiratory syncytial virus. It also produces an allogeneic off-the-shelf multi-virus specific T cell therapy dubbed posoleucel, for the treatment of JC virus, human herpes virus 6, Epstein-Barr virus, adenovirus, cytomegalovirus and BK virus.

The firm recently commenced a phase III trial on the effectiveness of its posoleucel formulation in treating fatal viral infections. It remains focused on advancing its T cell platform and evolving into a commercial stage firm, which will be good for its revenues as well as its investments.

Allovir Inc. (ALVR), closed Wednesday's trading session at $6.55, off by 0.907716%, on 174,124 volume. The average volume for the last 3 months is 173,125 and the stock's 52-week low/high is $6.2653/$26.41.

Premier Biomedical (BIEI)

QualityStocks, MoneyTV, TopPennyStockMovers, PennyStocks24, The Observer, SmallCapVoice, Promotion Stock Secrets, PennyStockRumors.net, PennyPro, Innovative Marketing, Information Solutions Group and FeedBlitz reported earlier on Premier Biomedical (BIEI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Premier Biomedical Inc. (OTC: BIEI) is a research-based firm that is focused on the discovery and development of medical products for the treatment of various ailments, including cancer and post-traumatic stress disorder.

The firm has its headquarters in Jackson Center, Pennsylvania and was incorporated in 2010, on May 10th by Mitchell S. Felder. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company’s objective is to conclude the development of potential medications which address various health issues and bring them to market. It is particularly focused on targeting the treatment of cancer, viremia, blood sepsis, traumatic brain injury, fibromyalgia, amyotrophic lateral sclerosis, multiple sclerosis and Alzheimer’s disease.

The enterprise develops a drug formulation dubbed Feldetrex, for traumatic brain injuries, neuropathic pain, fibromyalgia and multiple sclerosis. It is also focused on developing hemp oil products including hemp oil capsules, tincture drop products, ointments, sprays, roll-on topical products, anti-pain patch and pet products; sequential-dialysis technique for leukemia, blood sepsis, amyotrophic lateral sclerosis, Alzheimer’s disease and cancer. The enterprise also provides ointments through its painreliefmeds.com site and other distributors; oil-based pump spray applicators; oil-based and water-based roll-on applicators; and pain management products, including pain relief patch of hemp oil extracts. These targeted medicines prove out their superior effectiveness by addressing these illnesses via other applications.

The company continues to operate as an advanced research and development arm of the large pharmaceutical company, which will open it up more opportunities for growth, expansion and investments.

Premier Biomedical (BIEI), closed Wednesday's trading session at $0.0018, up 12.5%, on 9,609,845 volume. The average volume for the last 3 months is 9.61M and the stock's 52-week low/high is $0.001/$0.0072.

Up Fintech (TIGR)

MarketClub Analysis, Schaeffer's, TradersPro, StreetInsider, StockMarketWatch, InvestorPlace, MarketBeat, Jason Bond, Trades Of The Day, The Street, OTC Markets Group, Greenbackers and Daily Trade Alert reported earlier on Up Fintech (TIGR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Up Fintech Holding Ltd. (NASDAQ: TIGR) (FRA: 1M5) (BMV: TIGRN) is an online brokerage company that is engaged in the provision of brokerage services online, with a focus on global investors.

The firm has its headquarters in Beijing, China and was incorporated in 2014 by Tian Hua Wu. It operates as part of the capital markets industry, under the financial services sector. The firm serves consumers in the People’s Republic of China.

The company’s proprietary mobile and online trading platform allows investors to trade in warrants, options, equities and stocks, which can be accessed via its website and application on various exchanges around the globe. Its advanced technology also supports trades across multiple markets, multiple clearinghouses, multiple execution venues, multiple products and multiple currencies. The company is known as Tiger Brokers in Asia.

The enterprise provides account management services and value-added and brokerage services, which include IR platform, community engagement and investor education. It also provides simulated trading and market information services. In addition to this, the enterprise offers IPO underwriting services; fund structuring and management services; funding allocation, transaction execution, asset custody, product design and fund license application services; ESOP management services; wealth management and asset management services; and securities lending, margin financing and trade execution services.

The firm released its latest financial results recently which show an increase in its revenues. It remains focused on executing its global expansion strategy, which will help extend the firm’s consumer reach as well as bring in more investors and revenues into the firm.

Up Fintech (TIGR), closed Wednesday's trading session at $5.2, off by 2.9851%, on 3,335,760 volume. The average volume for the last 3 months is 3.165M and the stock's 52-week low/high is $2.68/$29.93.

SG Blocks Inc. (SGBX)

BUYINS.NET, StockMarketWatch, MarketClub Analysis, QualityStocks, InvestorPlace, Profitable Trader Authority, Buzz Stocks, HotOTC, OTCtipReporter, Penny Pick Finders, PennyStockScholar, TradersPro, Real Pennies, StockOnion, StreetInsider, TopPennyStockMovers and PennyStockProphet reported earlier on SG Blocks Inc. (SGBX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SG Blocks Inc. (NASDAQ: SGBX) (FRA: 9DS1) is a construction and design services firm that is focused on designing and modifying purpose-built modules for residential, industrial and commercial building construction and code-engineered cargo shipping containers.

The firm has its headquarters in Jacksonville, Florida and was incorporated in 1993, on December 29th. It operates as part of the industrial products industry, under the industrial intermediate products sub-industry, in the industrials sector. The firm serves consumers in the United States.

The company is focused on meeting the growing demand for safe and green construction. It has developed technology to break away from container construction at decreased costs. The company is committed to offering a construction methodology which will reduce the international carbon footprint.

The enterprise is focused on redesigning, repurposing and converting steel cargo shipping containers (heavy-gauge) into SGBlocks, which are green blocks used in construction. This eliminates the need to consume new lumber and steel in building. Its products allow builders and developers to achieve stronger buildings of higher value, extended life, faster execution and greener construction. The enterprise has an interest in meeting sustainable and safe housing needs, particularly in earthquake and hurricane prone areas. It serves owners, builders, architects and developers.

The firm recently entered into a 10-year distribution agreement with a global waste management firm known as Sanitec. This move will bolster the sales of Sanitec technology while bringing in more growth opportunities into the firm, which will positively influence its investments and revenue.

SG Blocks Inc. (SGBX), closed Wednesday's trading session at $2.39, up 3.913%, on 470,262 volume. The average volume for the last 3 months is 469,318 and the stock's 52-week low/high is $1.60/$5.7399.

Supernova Energy (SPRN)

Profitable Trader Authority, OTCtipReporter, PennyStockScholar, Small Cap Firm, Damn Good Penny Picks, Penny Picks, SmallCapInvestorDaily, OnPoint Stock Alert, Penny Stock Newsletter, Penny Stock 101, PHUB News, PREPUMP STOCKS, PennyStocks24, ProTrader, QualityStocks, Shiznit Stocks, Smallcap Invetment, StockRockandRoll, DSR News, Penny Stock Craze, Insider Wealth Alert, InvestorSoup, Jet-Life Penny Stocks, FivedollarMovers.net, Equities.com, GrowthPennyStocks, Penny Stock Finder, Penny Stock General, Penny Stock Titans, Penny Stocks Finder, Beacon Equity Research, PennyStockLocks.com, Wall Street Mover, PennyTrader, PoliticsAndMyPortfolio.com, Promotion Stock Secrets, Stock Commander, Stock Preacher, SuperStockTips, Value Penny Stocks and PennyStockLocks reported earlier on Supernova Energy (SPRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Supernova Energy, Inc. (OTC: SPRN) is an oil and gas exploration and production firm that explores for gas and oil properties.

The firm has its headquarters in Rockville Center, New York and was incorporated in 2009, on June 22nd by Geoffrey B. Scales. Prior to its name change in October 2013, the firm was known as Northumberland Resources Inc. It operates as part of the oil & gas E&P industry, under the energy sector. The firm serves consumers in the United States.

The enterprise’s objective is to develop a balanced portfolio of interests in exploration licenses in a non-operator role. It offers wellbore re-completion and completion services for small, independent contractors with existing oil and gas production. The enterprise’s consulting services include turnkey solutions, project management, well engineering services, workover, recompletion and completion. It also has properties primarily in Kansas. These properties comprise of over 85 gas, oil and SWD wells with interests in more than 2,000 acres of leaseholds. In addition to this, the enterprise holds a 50% working interest on the Monroe Lease, which has two producing wells which are about 1,200 ft deep. It is also focused on exploring for precious minerals.

The company recently established a new subsidiary, KLIR Sky Inc., which entered into a distribution agreement to sell gas processing and liquefaction systems. The subsidiary plans to use these systems to decrease or eliminate most greenhouse gases, which not only helps fight climate change but will also bring in additional revenue and investors into the company and extend its reach.

Supernova Energy (SPRN), closed Wednesday's trading session at $0.019, up 25.8278%, on 1,721,113 volume. The average volume for the last 3 months is 1.721M and the stock's 52-week low/high is $0.003/$0.019.

Aileron Therapeutics (ALRN)

TradersPro, MarketBeat, StreetInsider, QualityStocks, InvestorPlace, BUYINS.NET, WiseAlerts, StockMarketWatch and Barchart reported earlier on Aileron Therapeutics (ALRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aileron Therapeutics Inc. (NASDAQ: ALRN) (FRA: O15) is a clinical stage biopharmaceutical firm that is engaged in developing and commercializing a new class of therapeutics to help treat myelodysplastic syndrome, acute myeloid leukemia, cancer and other ailments.

Aileron Therapeutics Inc. is based in Watertown, Massachusetts and was incorporated in 2001 by Loren David Walensky, Joseph A. Yanchik III, Huw M. Nash, Rosana Kapeller and Gregory L. Verdine. Before changing its name in February 2007, the firm was known as Renegade Therapeutics Inc.

Aileron Therapeutics serves consumers in the United States and is party to a collaboration agreement with Pfizer to assess the combination of IBRANCE and ALRN-6924 in MDM2-amplified cancers and another with DANA-Farber/Boston Children’s Cancer and Blood Disorders Center for a multi-center, open-label, pediatric phase I ALRN-6924 clinical trial.

The Aileron Therapeutics Inc. product portfolio includes a peptide that permeates cells and reactivates tumor suppression in p53 cancers that are not mutated. The product called ALRN-6924, is currently undergoing a phase 1b clinical trial to test a combination of cytarabine and ALRN-6924 in patients with myelodysplastic syndromes; phase 1 clinical trial to evaluate its efficacy in treating advance myelodysplastic syndrome and acute myeloid leukemia; a phase 2a clinical trial for peripheral T-cell lymphoma and a phase 2a clinical trial to test its effectiveness in treating advanced solid tumors.

Aileron Therapeutics Inc. recently reported that data from the phase 1b study conducted on its ALRN-6924 candidate, which assesses its potential as a therapeutic agent that prevents chemotherapy-induced toxicities, may be used to improve the tolerance for chemotherapy for many cancer patients as well as better their quality of life.

Aileron Therapeutics (ALRN), closed Wednesday's trading session at $0.69, up 9.5238%, on 1,304,303 volume. The average volume for the last 3 months is 1.299M and the stock's 52-week low/high is $0.36/$1.45.

Fang Holdings (SFUN)

StocksEarning, MarketClub Analysis, Marketbeat, INO.com Market Report, The Street, StreetInsider, Marketbeat.com, Zacks, StreetAuthority Daily, StockMarketWatch, Schaeffer's, Investment House, StockEarnings, Money Morning, The Weekly Options Trader, Hit and Run Candle Sticks, Trading Concepts, ChartAdvisor, Market FN, Louis Navellier, Dynamic Wealth Report, Greenbackers, CrashTrade, BUYINS.NET, Barchart, FNNO Newsletters, Investing Futures, All about trends, QualityStocks, Rick Saddler, Stock Tips Network, Stockwire, Top Pros' Top Picks, Wealth Insider Alert, Weekly Wizards, Wyatt Investment Research and OTC Journal reported earlier on Fang Holdings (SFUN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fang Holdings Ltd (NYSE: SFUN) is a home furnishing improvement and real estate internet portal.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 1999, on June 18th by Tianquan Vincent Mo. Prior to its name change in September 2016, the firm was known as SouFun Holdings Ltd. It has four companies in its corporate family and serves consumers in China.

The company is focused on its real estate business, which it runs through a mobile application as well as www.fang.com, its web platform. The site serves as a one-stop avenue for users who wish to purchase accommodation facilities, office buildings and homes available in various regions in China. It generates most of its revenue from the sale of new homes via its e-commerce platform. A portion of the company’s income is also generated from financial, listing and marketing services.

The enterprise’s service offerings include financial services, listing services, e-commerce services and marketing segments. It also offers secured loans in the form of mortgage loans and entrusted loans as well as unsecured loans. The enterprise also supports active online communities and networks of users who seek information on value-added services for the home furnishing, improvement and real estate sectors.

As of September 2021, the company had about 70 offices which focused on local market needs in China and real estate content from more than 650 cities on its database and website. Expanding will not only extend the company’s consumer reach but also bring in more investments, which will be good for its growth.

Fang Holdings (SFUN), closed Wednesday's trading session at $4.3927, up 17.1387%, on 76,311 volume. The average volume for the last 3 months is 75,852 and the stock's 52-week low/high is $3.38/$12.59.

Cadiz Inc. (CDZI)

MarketBeat, InvestorGuide, MarketClub Analysis, MissionIR, StockMarketWatch, SmallCap Network, BUYINS.NET, Daily Trade Alert, Investing Futures, Investor Update, Schaeffer's, Tiny Gems, SmallCapInvestor.com, StockOodles, StreetInsider, The Street and QualityStocks reported earlier on Cadiz Inc. (CDZI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cadiz Inc. (NASDAQ: CDZI) (LON: 0HS4) (FRA: 2ZC) is a natural resources development firm that is involved in the acquisition, development and management of land with water resources for different uses.

The firm has its headquarters in Los Angeles, California and was incorporated in 1983 by Keith Brackpool. It serves consumers in the United States.

The company is committed to delivering opportunities to increase water access in California. Its main business involves acquiring and developing land with water resources for different uses, including agriculture, groundwater storage and groundwater supply. The company’s projects include the Cadiz Valley Water Recovery, Storage and Conservation.

The enterprise’s primary focus in the development of a water project dubbed the Water Project, which is located in its Cadiz Valley property. The project delivers new water to communities in California. Its properties represent private lands with vested water rights situated in parts of the San Bernardino County. The enterprise also owns roughly 9,000 acres of land in Piute Valley, 2,000 acres of land in the Danby Dry Lake region, nearly 35,000 acres of land in the Cadiz Valley and about 45,000 acres in 3 areas in the Mojave Desert region in Southern California. It is also involved in the fall and spring plantings of grains and vegetables as well as growing lemons.

The firm recently reported a new Schedule 13D by Heerema International Group Services. This move offers support to the company’s strategy to introduce new water storage, supply and conveyance assets which meet the needs of those with water supply shortages. This will positively influence the firm’s revenues as well as its growth.

Cadiz Inc. (CDZI), closed Wednesday's trading session at $2.41, up 9.0498%, on 628,220 volume. The average volume for the last 3 months is 594,283 and the stock's 52-week low/high is $1.66/$14.69.

Gratomic Inc. (CBULF)

QualityStocks and equities Canada reported earlier on Gratomic Inc. (CBULF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gratomic (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82) today announced its entry into a project agreement with the National Research Council of Canada (“NRC”) to evaluate the performance of spherical graphite samples extracted and supplied by Gratomic. Canada's largest federal research and development organization, the NRC offers a variety of services, including expertise and infrastructure for clean and energy-efficient transportation applications. As part of the project, the NRC will perform half-cell testing (a method of testing the viability of battery materials) in coin cells (small disc-shaped battery) of coated anodes based on Gratomic's spherical graphite samples. The NRC will measure the reversible capacity (the accumulation of surplus capacity) and the initial coulombic efficiency (the ratio of output versus input charge of a battery) and provide a summary report with the test results for 10 different samples. Phase one of the project consists of making and processing the electrodes, which involves a series of precision tasks, while the second phase will focus on testing the anodes.

To view the full press release, visit https://ibn.fm/Yb7pL

About Gratomic Inc.

Gratomic is a multinational company with projects in Namibia, Brazil and Canada. The company is focused on becoming a leading global graphite supplier and aims to secure a strong position in the electric vehicle (“EV”) battery supply chain. With the continued development of its flagship Aukam project and further exploration on the company's Capim Grosso property, Gratomic sets itself apart by seeking out unique top-quality assets around the world. True to its roots, the company will continue to explore graphite opportunities displaying potential for development. The company ranked third place in the top 10 preforming mining stocks on the 2022 TSX Venture 50(TM). Large quantities of high-quality vein graphite have been shipped for testing to confirm its viability as an anode material. Gratomic is confident that the test results will provide a unique competitive advantage in its desired target markets. The company will continue to update the public on the status of these tests and will provide results as soon as they become available. The company has formed a collaboration agreement with Forge Nano. With its patented Atomic Layer Deposition (“ALD”) coating, this cooperation with Forge Nano is a key element to support Gratomic's strategies towards the value-added phases of production of graphite for anode applications, namely micronization, spheronization and coating, making Gratomic graphite a preferred choice for use in lithium-ion batteries. For more information about the company, visit www.Gratomic.ca.

Gratomic Inc. (CBULF), closed Wednesday's trading session at $0.612, off by 0.439239%, on 35,966 volume. The average volume for the last 3 months is 35,966 and the stock's 52-week low/high is $0.532224/$1.50.

FSD Pharma Inc. (HUGE)

Schaeffer's, QualityStocks, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, has provided updates on four key issues. The updates noted that FSD Pharma has appointed industry leaders Jason Sawyer and Dr. Ravinder Kumar to its advisory board and has been working to expand its team at all levels to synergize its operations; those efforts include appointing Dr. Andrzej Chruscinski as associate vice president of clinical affairs; Kevin Cassidy as vice president of quality systems; and Dr. Oksana Akhova as director, licensing, partnership and IP. In addition, FSD Pharma reported that it has returned to treasury 1,524,700 shares as of March 31, 2022, through its buyback program, and the company has adopted the RSU program and issued RSUs in lieu of options held by directors and senior management.

To view the full press release, visit https://ibn.fm/FlrFv

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultramicronized palmitoyl ethylamine (“PEA”) or FSD-PEA, formerly called FSD-201. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Wednesday's trading session at $0.855, off by 1.7241%, on 96,604 volume. The average volume for the last 3 months is 94,241 and the stock's 52-week low/high is $0.80/$2.25.

The QualityStocks Company Corner

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD) (FSE: 80W), an agri-food tech company specializing in eco crop protection that helps reduce food waste and ensure food safety, published a letter to its stockholders from CEO David Palach. “We achieved multiple significant milestones in 2021, successfully transitioning Save Foods from a research and development focused organization to a commercial enterprise, fueled by the transformational May 2021 listing of our common stock on the Nasdaq Capital Market through an initial public offering that raised gross proceeds of $12 million. Even though we were an R&D focused company for much of 2021, and despite ongoing travel impacts related to COVID-19, I am pleased to report our team delivered 89% revenue growth over 2020,” Palach states in the letter. “With the capital in place to begin executing our vision in earnest, we embarked on an ambitious agenda in the second half of the year to accelerate our penetration into key markets and fortify our foundation for long-term growth. As part of that foundation, we completed the build-out of Save Foods Ltd.’s new headquarters and R&D center in Neve Yarak, Israel, providing ample room for our growing team to perform as we scale our operations in the fiscal quarters ahead. This facility completements our growing global network of agents in Mexico, Turkey, Egypt, South Africa, and Peru.” To view the full press release, visit https://ibn.fm/lw7Fq

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Wednesday's trading session at $5.63, up 4.0665%, on 64,363 volume. The average volume for the last 3 months is 64,363 and the stock's 52-week low/high is $3.4001/$18.00.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start at 1:10 p.m. ET. The panel discussion, which is titled “Short, Medium, and Long Term Catalysts in Psychedelics,” is scheduled for 3:10 p.m. ET. Archives versions of both events will be available on the company’s investor relations website. To listen to both the chat and the panel discussion, visit, visit https://ibn.fm/zlEC5. To view the full press release, visit https://ibn.fm/L1qah. New studies have found that exercising for 30 minutes may boost the benefits of therapy and decrease symptoms of depression for at least an hour and 15 minutes post workout. The studies were carried out by Iowa State University researchers, led by Professor Jacob Myer, who was also the lead author. The objective of the research was to find out how exercising influenced the symptoms of depression. For their first study, the researchers recruited 30 adults who experienced major depressive episodes. Each participant was required to fill out surveys, which included the scales used to measure a number of cognitive tasks and symptoms of depression as well as standard questions. The participants filled out these surveys before, during and after a half-hour session of either sitting or moderate-intensity cycling and then again 25, 50 and 75 minutes post workout. In the not-so-distant future, people diagnosed with depression could also benefit from the therapeutic effects of psychedelics, including psilocybin, if the R&D work being conducted by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) bears fruit and receives regulatory approval.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.82, up 0.99766%, on 969,630 volume. The average volume for the last 3 months is 962,014 and the stock's 52-week low/high is $0.70/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced its receipt of approval from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (“CPP Sud-Est III”) in France for the company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “Access to patients is the lifeblood of any clinical study and this approval, in the second most populous country in Europe , provides just that for our Berubicin trial. We have said time and again that our number one priority is the advancement of this potentially pivotal study. This is evidenced by our continuous dedication to driving enrollment and bringing global clinical sites on line,” said John Climaco, CEO of CNS Pharmaceuticals. “We are grateful to the French Competent Authority and Ethics Committee and their positive feedback on what we believe is an incredibly important clinical program. Across the globe there is an urgent need for GBM treatment options. We will continue to press on in our efforts to advance Berubicin through the clinic and importantly, to patients and their families. I am proud of the progress our team has made to-date and believe there are additional clinical sites to join those that have already been added to this global potentially pivotal study.” To view the full press release, visit https://ibn.fm/1kw0C

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.4239, up 11.6408%, on 3,134,264 volume. The average volume for the last 3 months is 3.134M and the stock's 52-week low/high is $0.2453/$2.68.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

The last person you would expect to use cannabis would be a “person of the cloth.” However, Craig Gross isn’t a conventional Christian. Like many people who grew up during the prohibition era, he’s heard plenty of stories regarding the evils of cannabis. And in Gross’ case, he may have been taught to avoid drugs such as cannabis. Despite that, Gross, now a Christian evangelist and entrepreneur, uses cannabis to alleviate a physical condition. Actually using marijuana after years and years of negative messaging required plenty of mental fortitude. Once Gross made the leap, the controversial plant provided effects he couldn’t have possibly foreseen. The spiritual angle of cannabis that this California-based pastor is emphasizing reveals how versatile the applications of the marijuana products made by legal entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) can be for different sections of the community.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Wednesday's trading session at $0.02825, up 4.6296%, on 424,290 volume. The average volume for the last 3 months is 424,290 and the stock's 52-week low/high is $0.014794/$0.13.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX) markets and sells advanced, self-contained hydroponic containers called Grow Pods; the patented Medtainer(R), a water-tight, air-tight, smell-proof, child-resistant, medical-grade herb container and grinder; and related products, such as humidity controllers and LED lighting systems for vertical farming. Medtainers may be used to store pharmaceuticals, herbs, teas, and other solids or liquids and can grind solids and shred herbs. The company also provides private labeling and branding services for purchasers of Medtainers and certain related products. At the same time, Advanced Container Technologies is currently the sole U.S. distributor of Grow Pods, developed and manufactured by GP Solutions Inc., having entered the Grow Pod business in October 2020 with the acquisition of all shares of Advanced Container Technologies Inc., a California corporation. “As of Feb. 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all the liabilities of GP Solutions Inc.,” a recent article reads. The Grow Pods offer a self-contained, indoor “micro-farm” environment that also features unique and innovative automated systems, meaning the Grow Pods can be placed virtually anywhere. With their controlled and specially filtered environment, they allow the cultivation of a wide variety of crops closer to the point of consumption all year round. Moreover, “Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.” To view the full article, visit: https://cnw.fm/syRoa

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $1, even for the day, on 501 volume. The average volume for the last 3 months is 501 and the stock's 52-week low/high is $0.66/$5.00.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

The transition to the use of clean energy in the United States has led Democrats to call for more mining, with experts agreeing that for a much faster transition away from the use of fossil fuels, more mining needs to be done to help build new transportation and energy systems. Recently, President Joseph Biden ordered that resources be directed toward the support of new mining activities in the country. These activities will all be aimed at the acquisition of the minerals required to manufacture electric car batteries, including nickel, lithium, graphite, cobalt and manganese. The president’s order came after a hearing was held by the Senate Energy and Natural Resources Committee. The hearing included two representatives of mining firms and a trio of experts on the mining industry. The representatives were the CEOs of Uranium Energy Corp. Scott Melbye and Twin Metals’ Julie Padilla. As more mining activity, especially with regard to uranium starts taking place domestically, there will be a strong economic case for the uranium extracted by companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) to be processed locally rather than being shipped overseas for processing.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $8.93, off by 0.223464%, on 3,544,234 volume. The average volume for the last 3 months is 3.485M and the stock's 52-week low/high is $4.32/$11.39.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has sought to fulfill the need for personalized financial information within the ever-expanding North American retail investor base. “SRAX, and its investor intelligence platform, Sequire, have looked to cater to the rapidly rising population of retail, high-net-worth, and institutional investors and their need for financial information and interaction amongst their peers. Since its inception, Sequire has seen its community swell to over nine million influential, forward-thinking investors and shareholders, firmly establishing itself as a venue where investors can congregate to learn, share and network on a wide range of industry-related topics,” a recent article reads. “Ranging from curating educational opportunities with leading investors and industry experts through masterclasses, to publishing a community newsletter to provide members with relevant and timely stock market and industry updates and hosting a wide array of virtual and in-person investor conferences every year, Sequire helps followers stay in the know and make informed investing decisions.” To view the full article, visit https://ibn.fm/Aqqtr

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $4.33, off by 3.7778%, on 71,079 volume. The average volume for the last 3 months is 71,069 and the stock's 52-week low/high is $3.53/$7.29.

Recent News

GreenBox POS (NASDAQ: GBOX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS (NASDAQ: GBOX).

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has completed its acquisition of Transact Europe Holdings (“TEU”). According to the company, the $28 million purchase price was substantiated by the value of Transact Europe’s business volume, strategic licenses, systems and personnel. An EU-regulated electronic money institution, TEU is headquartered in Sofia, Bulgaria, and holds an array of valuable licenses, including principal level membership of Visa, worldwide membership of MasterCard and principal membership of China UnionPay. “This acquisition is a momentous triumph for us, representing the most significant asset to date for GreenBox, allowing us to propel forward as a significant player in the European and global marketplace,” said GreenBox chair Ben Errez in the press release. “GreenBox and TEU are a natural complement to each other with TEU’s licenses and infrastructure combined with GreenBox’s suite of customized blockchain payment solutions, global strategy and technology creating a powerful synergy that we believe will quickly scale in the European market in which noncash payments account for over 100 billion transactions and exceed 160 trillion euros per year. Furthermore, our combined infrastructure paves the way for expansion into other digital payments markets and countries around the world. As a result, we expect to see momentous gains in processing volume leading to stronger revenue contribution and long-term sustainable value our shareholders expect.” To view the full press release, visit https://ibn.fm/z30Y8

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary security and token technology to build customized payment solutions for business. The company’s mission is to build compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving and dynamic global market.

GreenBox applications enable an end-to-end suite of turnkey financial products which offer improved fraud detection and better handling efficiency of large-scale commercial payment processing volumes for its merchant clients globally. The company’s proprietary blockchain and smart contract token technologies create seamless payment processing using digital encryption keys.

GreenBox is a unified platform providing scalability for businesses to accept payments, transact, send, settle and convert in a single versatile ecosystem. GreenBox operates a private and proprietary blockchain-based payment platform that offers distinct advantages when compared to traditional payment technologies, including greater security and data privacy, as well as enhanced identity theft protection and quick settlement.

As the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time for Tier-1 partners around the world.

In November 2021, GreenBox announced the closing of a previously announced $100 million convertible note financing. The company plans to use proceeds for acquisitions, a planned stablecoin spin-off, and additional working capital toward the company’s future growth. The initial conversion price equals a more than 80 percent premium to the market price of the company’s common stock on October 29, 2021, and values the enterprise at more than $700 million upon conversion.

Brands & Solutions

The company offers multiple solutions and brands under the GreenBox label. The other brands that are nested under the GreenBox POS label include coyni, ChargeSavvy, QuickCard, Transact Europe [didn’t yet close] and Northeast Merchant Systems. Each of these brands play a large role in allowing GreenBox to accel in customizing payment solutions across different verticals and industries.

Payment Solutions

The GreenBox platform offers blockchain secure, robust payment processing solutions for both individual consumers and businesses. The company combines the power and security of blockchain with bank-level tools necessary to both settle transactions and monitor cash flows. Customers can transfer cryptocurrencies like USDC, Ethereum or Bitcoin from external decentralized crypto wallets to their GreenBox wallets. They can also exchange those tokens from their GreenBox wallets to any supported coin. Customers can easily offload in USDC to a debit card or a multitude of gift cards.

White Label Solutions

The company’s white label platform allows it to partner with firms seeking blockchain-based tools to manage merchant relationships. White label partners can monitor cash flows, as well as run reports on merchant transactions, chargebacks, agent and affiliate commissions and more. Partners can access the platform through their partner portal to manage business relationships with full visibility. The platform’s cutting-edge technology saves partners time and simplifies their payment processing. It ensures compliance with automated Know Your Customer and Know Your Bank services and allows customers to set up automated payouts.

coyni Stablecoin

The company is planning soon to launch its own stablecoin, coyni (CYN). coyni is equivalent to the value of the U.S. dollar on a one-to-one ratio. Stablecoin allows for instantaneous transactions with blockchain security just like other cryptocurrency tokens, but without the price volatility of traditional cryptocurrencies. The CYN token is expected to make possible features like digital dollar accounts, cross border payments, international payment processing and other payment solutions. As a smart contract technology, coyni will offer instant settlement using the GreenBox blockchain ledger in any location and currency – crypto or fiat – all at lower fees and in a tokenized secure ecosystem.

Market Overview

A Mordor Intelligence report put the transaction value of the global digital payments market at $5.44 trillion in 2020 and projects the market to be worth $11.29 trillion by 2026. That represents a CAGR of 11.21 percent during the period of 2021-2026.

The report notes that the global COVID-19 pandemic and its impact on e-commerce is likely to encourage strengthened international cooperation and further development of policies for online purchasing and supply. The report states, “The pandemic has made it clear that e-commerce can be an important tool/solution, especially considering the fact that e-commerce sales can support small and medium businesses that form the backbone for certain economies. This is expected to substantially spur the growth of digital payment methods across various economies.”

According to Mordor, other drivers of the growth trend in digital payments include:

  • Greater convenience, favorable government policies and evolving consumer behavior worldwide
  • Rapid rise in smartphone penetration throughout emerging economies
  • Introduction of mobile wallets across the world
  • Widespread adoption of retail digital payment services across the vast population of China, serving as a kind of test case for other countries

Management Team

Ben Errez, Chairman of the Board of Directors

Ben Errez’s past positions have included positions at large companies like Microsoft and Intel. He has brought this expertise to lead GreenBox into the forefront of the blockchain-based financial software, services, and hardware market.

Mr. Errez was one of the early managers of Microsoft in 1991. From 1991 to 2004, he served as Software Development Lead for the Microsoft International Office Group. He led the International Microsoft Office Components team (Word, Excel, PowerPoint) in design, engineering, development, and successful deployment. He also served as Executive Representative of Microsoft Office and was a founding member of the Microsoft Trustworthy Computing Team both within the company and internationally. Mr. Errez co-authored the first Microsoft Trustworthy Computing Paper on Reliability. At Microsoft, he was responsible for the development of the first Microsoft software translation Software Development Kit (“SDK”) in Hebrew, Arabic, Thai, and Simplified Chinese, as well as the development of the first bidirectional extensions to Rich Text Format (“RTF”) file format and all bidirectional extensions in text converters for Microsoft Office. He also contributed to the development of the international extensions to the Unicode standard to include bidirectional requirements under the World Wide Web Consortium (“W3C”).

In 2004, Mr. Errez transitioned into the world of consulting, where he held the position of Principal Consultant from founding to the present date, through which he advises clients in the South Pacific region with market capitalizations ranging from $50 million to $150 million on commerce, security, reliability, and privacy.

In 2017, immediately before partnering with Fredi Nisan to launch GreenBox, Mr. Errez was asked to take over the Microsoft Alumni Network for the Southern California region as a regional director. Mr. Errez has been a principal of GreenBox since its inception in 2017.

Fredi Nisan, Chief Executive Officer

Fredi Nisan’s career in technology began during his years of service in the Israeli Defense Forces, where he served as IT Manager for all of Israel’s Northern Bases. After serving in the military, Mr. Nisan opened and operated a computer hardware store before becoming the Inventory Operations Manager for Zicon Israel in 2005, a hardware and software producer. At Zicon, he supervised inventory operations, worked on quality controls for motherboards and chips, and educated customers on software and hardware product functionality. Subsequently, Mr. Nisan moved to the United States, where he worked for One Coach in San Diego, California, as a business coach. One Coach specializes in customized growth solutions for small business owners, including the latest strategies for sales, internet marketing, branding, and ROI. Mr. Nisan was consistently ranked as the top salesperson for small business coaching while working with One Coach.

In 2010, Mr. Nisan launched Brava POS, where he served as President until 2015. Brava POS provided point of sale (“POS”) systems for specialty retail companies. Mr. Nisan developed software to provide clients with solutions for issues ranging from inventory management to payroll to processing high volume transactions in the form of a cloud-based POS system. This system had the capability to manage multiple stores with centralized inventory and process sales without an internet connection, and offered a secure login for each employee, as well as including advanced inventory management and reporting, plus powerful functionality for its end users.

In 2016, Mr. Nisan founded Firmness, LLC. Through Firmness, he created “QuickCitizen,” a software program that simplifies the onboarding process for new clients of law firms specializing in immigration issues. The QuickCitizen software significantly reduced law firms onboarding processing time from more than three hours to approximately 15 minutes. Mr. Nisan has been a principal of GreenBox since its August 2017 inception. In January 2018, Firmness sold QuickCitizen to GreenBox.

Jacquline B. Reynolds, Chief Marketing Officer

Jacqueline B. Reynolds is the company’s Chief Marketing Officer. She served most recently as vice president of marketing for Sprouts Farmers Market. She has built her reputation as a world-class global marketer, working with Coca-Cola, McDonald’s, Verizon, Walmart, L’Oréal, Xbox, 7-Eleven and many other Fortune 500 brands. She has managed award-winning marketing programs with partners such as the NFL, Super Bowl LIV, the Olympics, the FIFA World Cup, Sony Pictures, Universal Music and others.

GreenBox POS (NASDAQ: GBOX), closed Wednesday's trading session at $4.26, off by 2.2936%, on 295,066 volume. The average volume for the last 3 months is 295,066 and the stock's 52-week low/high is $2.24/$20.78.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

  • LiDARs have been one of key enablers for autonomous vehicle sector, but this unique technology offers use cases beyond automotive industry
  • Consumer Electronics Show, one of the world’s most influential tech events, demonstrates that LiDAR is growing within non-automotive landscape, including smart city/infrastructure and security
  • Cepton set to benefit as the Company has already established its presence in non-automotive, delivering LiDAR systems for smart cities, spaces, and industrial applications around the globe

Cepton (NASDAQ: CPTN), a Silicon Valley leader in innovative, high-performance LiDAR solutions, appears well-positioned to benefit as the non-automotive applications of the LiDAR technology grow. LiDAR technology seems to be on its path to move away from the realm of sci-fi-like promises toward real applications and commercialization. While the autonomous vehicle sector strives to make strides in terms of a safe and sustainable driving experience, for which LiDARs are one of the key enablers, the question remains as to what the future holds for this technology beyond the automotive sector? Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the BofA Securities Global Automotive Summit on April 13, 2022. According to the announcement, Cepton is scheduled to present at 1:20 p.m. ET on Wednesday, April 13. Interested parties may visit https://ibn.fm/Q4V6i to register to view a live webcast of the presentation. The registration link and Cepton’s investor presentation can also be found at https://investors.cepton.com. To view the full press release, visit https://ibn.fm/su7gC

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Wednesday's trading session at $3.7, off by 4.6392%, on 503,454 volume. The average volume for the last 3 months is 501,005 and the stock's 52-week low/high is $3.62/$80.16.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”)
  • The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs
  • Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more
  • According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success

In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners with third-party companies looking to explore formulation opportunities with their targeted APIs, out-licenses its technology, and is actively developing lead product candidates. According to a 2021 video, the company also hopes to provide a lifeline to pharmaceutical companies noting that DehydraTECH(TM) “may provide additional patent extensions for existing drugs, which is a potential billion-dollar insurance policy to original drug manufacturers” (https://cnw.fm/6OXrO).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $3.03, off by 3.8095%, on 54,727 volume. The average volume for the last 3 months is 54,727 and the stock's 52-week low/high is $2.64/$12.50.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

  • InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential
  • InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products
  • The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year
  • The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions, including glaucoma and a severe genetic skin disorder known as epidermolysis bullosa (“EB”)

Rare cannabinoid drug developer InMed Pharmaceuticals (NASDAQ: INM) is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year to better approach the pharmaceutical and health and wellness markets (https://cnw.fm/9lVDp). 

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Wednesday's trading session at $0.88625, off by 4.6017%, on 54,531 volume. The average volume for the last 3 months is 54,371 and the stock's 52-week low/high is $0.6521/$3.99.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

These last few years, clinical trials on the use of psychedelics such as MDMA, LSD or psilocybin as treatments for various mental health conditions have increased significantly. For clinical trials to run, however, participants are needed. At first glance, it may seem easy to enroll individuals for trials given that quite a number of people suffer from mental conditions such as depression and anxiety. However, for an individual to be enrolled into a clinical trial, they must meet the stipulated inclusion criteria in order to be eligible. Below are steps on how one can enroll in a psychedelic clinical trial. Given that various biopharmaceutical companies such as Silo Pharma Inc. (OTCQB: SILO) have interest in the therapeutic potential of psychedelics, it may no longer be difficult to identify studies that will be conducted near you and enroll as a study subject.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $0.222, off by 1.1576%, on 12,016 volume. The average volume for the last 3 months is 12,016 and the stock's 52-week low/high is $0.12/$0.39.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.